The Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market should witness market growth of 45.5% CAGR during the forecast period (2023-2029).
The growing awareness among patients and healthcare professionals of the potential benefits of live biotherapeutic products and microbiome-based treatments in a number of ailments, including cancer, inflammatory bowel disease (IBD), and neurological disorders.
The growing investment in LBP and microbiome-based medications by pharmaceutical and biotech companies are driving the demand for CDMOs specializing in these disciplines, and it's expected that trend will continue over the next ten years. As the demand for LBPs as well as microbiome-based therapies expands, businesses are searching for CDMOs with the expertise needed to develop and create these products.
Due to a number of factors, including the requirement for specialized facilities, tools, and operational know-how, innovative organizations have started turning to contract manufacturing for their microbiome-related research and production requirements. There are a number of advantages to outsourcing, including lower capital expenditures, quicker time-to-market, faster access to greater production capacity, and (to a major extent) better commercial risk handling as well as mitigation. Presently, a number of CMOs (contract manufacturing organizations) and CDMOs (contract development and manufacturing organizations) assert to provide services for producing items connected to the microbiome. Some in this industry have even created end-to-end capabilities, starting with drug discovery and ending with regulatory filings and commercial-scale production.
There has been a rise in the number of people diagnosed with cancer in this region. Additionally, a rise in the number of government programs to create healthcare infrastructure and the number of people who are susceptible to a variety of chronic diseases have increased the demand for novel and personalized therapies. These have been some of the primary drivers for the market in the region. Additionally, the introduction and research into the development of LBPs have the potential to have a favorable effect on the growth of markets in developed nations such as Australia, Japan, and New Zealand. It is for this reason that it is predicted that throughout the time of the forecast, these elements will present new growth chances for the players who are operating in the market.
The China market dominated the Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $4,656 Thousands by 2029. The Japan market is anticipated to grow at a CAGR of 44.6% during (2023-2029). Additionally, The India market would experience a CAGR of 46.4% during (2023-2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
The growing awareness among patients and healthcare professionals of the potential benefits of live biotherapeutic products and microbiome-based treatments in a number of ailments, including cancer, inflammatory bowel disease (IBD), and neurological disorders.
The growing investment in LBP and microbiome-based medications by pharmaceutical and biotech companies are driving the demand for CDMOs specializing in these disciplines, and it's expected that trend will continue over the next ten years. As the demand for LBPs as well as microbiome-based therapies expands, businesses are searching for CDMOs with the expertise needed to develop and create these products.
Due to a number of factors, including the requirement for specialized facilities, tools, and operational know-how, innovative organizations have started turning to contract manufacturing for their microbiome-related research and production requirements. There are a number of advantages to outsourcing, including lower capital expenditures, quicker time-to-market, faster access to greater production capacity, and (to a major extent) better commercial risk handling as well as mitigation. Presently, a number of CMOs (contract manufacturing organizations) and CDMOs (contract development and manufacturing organizations) assert to provide services for producing items connected to the microbiome. Some in this industry have even created end-to-end capabilities, starting with drug discovery and ending with regulatory filings and commercial-scale production.
There has been a rise in the number of people diagnosed with cancer in this region. Additionally, a rise in the number of government programs to create healthcare infrastructure and the number of people who are susceptible to a variety of chronic diseases have increased the demand for novel and personalized therapies. These have been some of the primary drivers for the market in the region. Additionally, the introduction and research into the development of LBPs have the potential to have a favorable effect on the growth of markets in developed nations such as Australia, Japan, and New Zealand. It is for this reason that it is predicted that throughout the time of the forecast, these elements will present new growth chances for the players who are operating in the market.
The China market dominated the Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $4,656 Thousands by 2029. The Japan market is anticipated to grow at a CAGR of 44.6% during (2023-2029). Additionally, The India market would experience a CAGR of 46.4% during (2023-2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
Scope of the Study
By Application
- C.difficile
- Crohns Disease
- IBS
- Diabetes
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 4. Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country
Chapter 5. Company Profiles
Companies Mentioned
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Methodology
LOADING...
